dyslipidemiaandmanagementofdyslipidemia-by muhammad-nizam-uddin
TRANSCRIPT
![Page 1: Dyslipidemiaandmanagementofdyslipidemia-by Muhammad-Nizam-Uddin](https://reader036.vdocument.in/reader036/viewer/2022062320/55c4f7a9bb61eb38508b46b4/html5/thumbnails/1.jpg)
Dyslipidemia and Management of Dyslipidemia
Prepared by:
Muhammad Nizam Uddin
![Page 2: Dyslipidemiaandmanagementofdyslipidemia-by Muhammad-Nizam-Uddin](https://reader036.vdocument.in/reader036/viewer/2022062320/55c4f7a9bb61eb38508b46b4/html5/thumbnails/2.jpg)
CHOLESTEROL A soft waxy substance found among
lipids (fats) in the bloodstream and all cells
Needed for digesting fats, making hormones, building cell walls
Carried in particles called lipoproteins that act as transport vehicles delivering cholesterol to various body tissues to be used, stored or excreted
Excess circulating cholesterol can lead to plaque formation- Atherosclerosis
![Page 3: Dyslipidemiaandmanagementofdyslipidemia-by Muhammad-Nizam-Uddin](https://reader036.vdocument.in/reader036/viewer/2022062320/55c4f7a9bb61eb38508b46b4/html5/thumbnails/3.jpg)
Structure of Lipoprotein
![Page 4: Dyslipidemiaandmanagementofdyslipidemia-by Muhammad-Nizam-Uddin](https://reader036.vdocument.in/reader036/viewer/2022062320/55c4f7a9bb61eb38508b46b4/html5/thumbnails/4.jpg)
Metabolism of Plasma Lipid
![Page 5: Dyslipidemiaandmanagementofdyslipidemia-by Muhammad-Nizam-Uddin](https://reader036.vdocument.in/reader036/viewer/2022062320/55c4f7a9bb61eb38508b46b4/html5/thumbnails/5.jpg)
HMG Co-A reductase is the rate limiting enzyme in the cholesterol synthesis.
Rate Limiting Enzyme
![Page 6: Dyslipidemiaandmanagementofdyslipidemia-by Muhammad-Nizam-Uddin](https://reader036.vdocument.in/reader036/viewer/2022062320/55c4f7a9bb61eb38508b46b4/html5/thumbnails/6.jpg)
DYSLIPIDEMIA
(A consequence of abnormal lipoprotein metabolism)
Elevated Total Cholesterol (TC) Elevated Low-density lipoproteins (LDL) Elevated triglycerides (TG) Decreased High-density lipoproteins (HDL)
![Page 7: Dyslipidemiaandmanagementofdyslipidemia-by Muhammad-Nizam-Uddin](https://reader036.vdocument.in/reader036/viewer/2022062320/55c4f7a9bb61eb38508b46b4/html5/thumbnails/7.jpg)
Causes of Dyslipidemia
![Page 8: Dyslipidemiaandmanagementofdyslipidemia-by Muhammad-Nizam-Uddin](https://reader036.vdocument.in/reader036/viewer/2022062320/55c4f7a9bb61eb38508b46b4/html5/thumbnails/8.jpg)
SINGLE OR MULTIPLE GENE MUTATION –RESULTING IN DISTURBANCE OF LDL, HDL AND TRIGYLCERIDE, PRODUCTION OR CLEARANCE.
Should be suspected in patients with premature heart disease family hx of atherosclerotic dx. Or serum cholesterol level >240mg/dl. Physical signs of hyperlipidemia.
Primary Dyslipidemia
![Page 9: Dyslipidemiaandmanagementofdyslipidemia-by Muhammad-Nizam-Uddin](https://reader036.vdocument.in/reader036/viewer/2022062320/55c4f7a9bb61eb38508b46b4/html5/thumbnails/9.jpg)
Secondary Dyslipidemia
Sedentary lifestyle Excessive consumption of cholesterol
– saturated fats and trans-fatty acids.
![Page 10: Dyslipidemiaandmanagementofdyslipidemia-by Muhammad-Nizam-Uddin](https://reader036.vdocument.in/reader036/viewer/2022062320/55c4f7a9bb61eb38508b46b4/html5/thumbnails/10.jpg)
Moderately commonHypothyroidism Pregnancy Cholestatic liver disease Drugs (diuretics, ciclosporin, corticosteroids,
androgens)
Less common Nephrotic syndrome Anorexia nervosa Porphyria Hyperparathyroidism
Secondary Dyslipidemia
![Page 11: Dyslipidemiaandmanagementofdyslipidemia-by Muhammad-Nizam-Uddin](https://reader036.vdocument.in/reader036/viewer/2022062320/55c4f7a9bb61eb38508b46b4/html5/thumbnails/11.jpg)
Secondary hypertriglyceridaemia
Diabetes mellitus (type 2) Chronic renal disease Abdominal obesity Excess alcohol Hepatocellular disease Drugs (β-blockers, retinoids,
corticosteroids)
![Page 12: Dyslipidemiaandmanagementofdyslipidemia-by Muhammad-Nizam-Uddin](https://reader036.vdocument.in/reader036/viewer/2022062320/55c4f7a9bb61eb38508b46b4/html5/thumbnails/12.jpg)
Classification of Dyslipidemia and Risk
![Page 13: Dyslipidemiaandmanagementofdyslipidemia-by Muhammad-Nizam-Uddin](https://reader036.vdocument.in/reader036/viewer/2022062320/55c4f7a9bb61eb38508b46b4/html5/thumbnails/13.jpg)
![Page 14: Dyslipidemiaandmanagementofdyslipidemia-by Muhammad-Nizam-Uddin](https://reader036.vdocument.in/reader036/viewer/2022062320/55c4f7a9bb61eb38508b46b4/html5/thumbnails/14.jpg)
Clinical manifestation of Dyslipidemia
![Page 15: Dyslipidemiaandmanagementofdyslipidemia-by Muhammad-Nizam-Uddin](https://reader036.vdocument.in/reader036/viewer/2022062320/55c4f7a9bb61eb38508b46b4/html5/thumbnails/15.jpg)
![Page 16: Dyslipidemiaandmanagementofdyslipidemia-by Muhammad-Nizam-Uddin](https://reader036.vdocument.in/reader036/viewer/2022062320/55c4f7a9bb61eb38508b46b4/html5/thumbnails/16.jpg)
Different ways of detection of dyslipidemia
![Page 17: Dyslipidemiaandmanagementofdyslipidemia-by Muhammad-Nizam-Uddin](https://reader036.vdocument.in/reader036/viewer/2022062320/55c4f7a9bb61eb38508b46b4/html5/thumbnails/17.jpg)
During routine health checkup
Clinical manifestation e.g. Xanthelesma
Associated diseases e.g. CHD,DM,HTN
BY DOCTOR BY PATIENT
![Page 18: Dyslipidemiaandmanagementofdyslipidemia-by Muhammad-Nizam-Uddin](https://reader036.vdocument.in/reader036/viewer/2022062320/55c4f7a9bb61eb38508b46b4/html5/thumbnails/18.jpg)
Lipid measurement
At least 12 hrs fasting
Friedwald formula:LDL-C= TC — HDL-C — ( TG/2.2)
mmol/L
Applicable up to TG: 4mmol/L
![Page 19: Dyslipidemiaandmanagementofdyslipidemia-by Muhammad-Nizam-Uddin](https://reader036.vdocument.in/reader036/viewer/2022062320/55c4f7a9bb61eb38508b46b4/html5/thumbnails/19.jpg)
Calculation of LDL
TC= HDL + VLDL + LDL
Þ TC = HDL + TG/5 + LDL
Þ LDL= TC — ( HDL + TG/5)
Applicable up to TG: 350 mg/dl
![Page 20: Dyslipidemiaandmanagementofdyslipidemia-by Muhammad-Nizam-Uddin](https://reader036.vdocument.in/reader036/viewer/2022062320/55c4f7a9bb61eb38508b46b4/html5/thumbnails/20.jpg)
Different Types of Cholesterol
![Page 21: Dyslipidemiaandmanagementofdyslipidemia-by Muhammad-Nizam-Uddin](https://reader036.vdocument.in/reader036/viewer/2022062320/55c4f7a9bb61eb38508b46b4/html5/thumbnails/21.jpg)
LDL- (“bad” cholesterol) The major cholesterol carrier in the blood. Excess most likely to lead to plaque formation. Goal: LOW
HDL- (“good” cholesterol) Transports cholesterol away from arteries and back to the liver to be eliminated. Removes excess cholesterol from plaques, slowing growth. Goal: HIGH
![Page 22: Dyslipidemiaandmanagementofdyslipidemia-by Muhammad-Nizam-Uddin](https://reader036.vdocument.in/reader036/viewer/2022062320/55c4f7a9bb61eb38508b46b4/html5/thumbnails/22.jpg)
Normal Level
![Page 23: Dyslipidemiaandmanagementofdyslipidemia-by Muhammad-Nizam-Uddin](https://reader036.vdocument.in/reader036/viewer/2022062320/55c4f7a9bb61eb38508b46b4/html5/thumbnails/23.jpg)
LDL Cholesterol (mg/dl) HDL Cholesterol (mg/dl)
<100 Optimal < 40 Low100-129 Near/Above Optimal > 60 High (Desirable)130-159 Borderline High160-189 High>190 Very High
Categories of Risk that Modify LDL GoalsCHD and CHD risk equivalents <100Multiple (2+) risk factors <130Zero to one risk factor <160
![Page 24: Dyslipidemiaandmanagementofdyslipidemia-by Muhammad-Nizam-Uddin](https://reader036.vdocument.in/reader036/viewer/2022062320/55c4f7a9bb61eb38508b46b4/html5/thumbnails/24.jpg)
Major Risk Factors For CHD That Modify LDL Goals
Cigarette smokingHypertension (BP >140/90 or on BP
med)Low HDL cholesterol (<40mg/dl)Family Hx premature CHD- CHD in male 1st degree relative <55 years old- CHD in female 1st degree relative <65 years old
Age (men >45 yrs. women >55 yrs) HDL >60 counts as a “negative” risk factor. It’s presence removes
one risk factor from the total count
![Page 25: Dyslipidemiaandmanagementofdyslipidemia-by Muhammad-Nizam-Uddin](https://reader036.vdocument.in/reader036/viewer/2022062320/55c4f7a9bb61eb38508b46b4/html5/thumbnails/25.jpg)
Risk Assessment for CHD
DM regarded as a CHD equivalent
For patients with multiple (2+) risk factors
-Perform 10 year risk assessment
For patients with 0-1 risk factor-Most have 10 year risk assessment
<10%; risk assessment scoring unnecessary
![Page 26: Dyslipidemiaandmanagementofdyslipidemia-by Muhammad-Nizam-Uddin](https://reader036.vdocument.in/reader036/viewer/2022062320/55c4f7a9bb61eb38508b46b4/html5/thumbnails/26.jpg)
Current ATP III Guidelines for Treating LDL Cholesterol
Risk Category
LDL Goal(mg/dl)
LDL level to initiate TLC
LDL level to consider Rx therapy
CHD or Equivalents
<100<70 Ideal
> 100 > 130(100-129 Rx optional)
2+ Risk Factors
<130 > 130 > 130 (10 Year risk 10-20%)> 160 (Risk <10%)
0-1 Risk Factor
<160 > 160 > 190(160-189 Rx optional)
![Page 27: Dyslipidemiaandmanagementofdyslipidemia-by Muhammad-Nizam-Uddin](https://reader036.vdocument.in/reader036/viewer/2022062320/55c4f7a9bb61eb38508b46b4/html5/thumbnails/27.jpg)
A Model of Steps in Therapeutic Lifestyle Changes (TLC)
Visit 1
Begin TLC
• Emphasize reduction in saturated fat & chol.
• Encourage moderate Physical activity
• Consider referral to dietician
Visit 2 (6 wks)
Eval. LDL response
Intensify Tx if not to goal
• Reinforce dietary recommendations
• Consider adding plant stanols/sterols
• Increase fiber intake
• Consider dietician
Visit 3 (6 wks)
Eval LDL response
Consider adding Rx if not to goal
• Evaluate for Metabolic syndrome
• Intensify wt mgmt & physical activity
• Consider dietician
Visit N
Monitor adherence to
TLC Q4-6 mos
![Page 28: Dyslipidemiaandmanagementofdyslipidemia-by Muhammad-Nizam-Uddin](https://reader036.vdocument.in/reader036/viewer/2022062320/55c4f7a9bb61eb38508b46b4/html5/thumbnails/28.jpg)
Specific Dyslipidemias: Elevated Triglycerides
Classification of Serum Triglycerides
Normal <150 mg/dl Borderline High 150-199 mg/dl High 200-499mg/dl Very High >500 mg/dl
![Page 29: Dyslipidemiaandmanagementofdyslipidemia-by Muhammad-Nizam-Uddin](https://reader036.vdocument.in/reader036/viewer/2022062320/55c4f7a9bb61eb38508b46b4/html5/thumbnails/29.jpg)
Specific Dyslipidemias: Elevated Triglycerides
Management of Very High Triglycerides (>500 mg/dl)
Goal of therapy: Prevent acute pancreatitis Very low fat diets (< 15% of caloric intake) Triglyceride-lowering drug usually required
(fibrate or nicotinic acid) Reduce triglycerides before lowering LDL
![Page 30: Dyslipidemiaandmanagementofdyslipidemia-by Muhammad-Nizam-Uddin](https://reader036.vdocument.in/reader036/viewer/2022062320/55c4f7a9bb61eb38508b46b4/html5/thumbnails/30.jpg)
Consequences of dyslipidemia
Atherosclerosis The main Consequence
Acute pancreatitis ( in High TG)
![Page 31: Dyslipidemiaandmanagementofdyslipidemia-by Muhammad-Nizam-Uddin](https://reader036.vdocument.in/reader036/viewer/2022062320/55c4f7a9bb61eb38508b46b4/html5/thumbnails/31.jpg)
Pathogenesis of Atherosclerosis
![Page 32: Dyslipidemiaandmanagementofdyslipidemia-by Muhammad-Nizam-Uddin](https://reader036.vdocument.in/reader036/viewer/2022062320/55c4f7a9bb61eb38508b46b4/html5/thumbnails/32.jpg)
Early Atherosclerosis
![Page 33: Dyslipidemiaandmanagementofdyslipidemia-by Muhammad-Nizam-Uddin](https://reader036.vdocument.in/reader036/viewer/2022062320/55c4f7a9bb61eb38508b46b4/html5/thumbnails/33.jpg)
Early Atherosclerosis
![Page 34: Dyslipidemiaandmanagementofdyslipidemia-by Muhammad-Nizam-Uddin](https://reader036.vdocument.in/reader036/viewer/2022062320/55c4f7a9bb61eb38508b46b4/html5/thumbnails/34.jpg)
Early Atherosclerosis
![Page 35: Dyslipidemiaandmanagementofdyslipidemia-by Muhammad-Nizam-Uddin](https://reader036.vdocument.in/reader036/viewer/2022062320/55c4f7a9bb61eb38508b46b4/html5/thumbnails/35.jpg)
Stable Atherosclerotic Plaque
![Page 36: Dyslipidemiaandmanagementofdyslipidemia-by Muhammad-Nizam-Uddin](https://reader036.vdocument.in/reader036/viewer/2022062320/55c4f7a9bb61eb38508b46b4/html5/thumbnails/36.jpg)
Advanced Atherosclerosis
![Page 37: Dyslipidemiaandmanagementofdyslipidemia-by Muhammad-Nizam-Uddin](https://reader036.vdocument.in/reader036/viewer/2022062320/55c4f7a9bb61eb38508b46b4/html5/thumbnails/37.jpg)
Unstable Coronary Artery Disease
![Page 38: Dyslipidemiaandmanagementofdyslipidemia-by Muhammad-Nizam-Uddin](https://reader036.vdocument.in/reader036/viewer/2022062320/55c4f7a9bb61eb38508b46b4/html5/thumbnails/38.jpg)
Management of Dyslipidemia
Risk assessment Treat modifiable risk factors Optimization of lifestyle factors
![Page 39: Dyslipidemiaandmanagementofdyslipidemia-by Muhammad-Nizam-Uddin](https://reader036.vdocument.in/reader036/viewer/2022062320/55c4f7a9bb61eb38508b46b4/html5/thumbnails/39.jpg)
Non pharmacologic management
Reduce intake of saturated and trans-unsaturated fat to less than 7-10% of total energy
Reduce intake of cholesterol to < 250 mg/day
Replace sources of saturated fat and cholesterol with alternative foods such as lean meat, low-fat dairy products, polyunsaturated spreads and low glycaemic index carbohydrates
![Page 40: Dyslipidemiaandmanagementofdyslipidemia-by Muhammad-Nizam-Uddin](https://reader036.vdocument.in/reader036/viewer/2022062320/55c4f7a9bb61eb38508b46b4/html5/thumbnails/40.jpg)
Non pharmacologic management
Reduce energy-dense foods such as fats and soft drinks
Increase consumption of cardioprotective and nutrient-dense foods such as vegetables, unrefined carbohydrates, fish, pulses, nuts, legumes, fruit etc.
Adjust alcohol consumption, reducing intake if excessive or if associated with hypertension, hypertriglyceridaemia or central obesity
![Page 41: Dyslipidemiaandmanagementofdyslipidemia-by Muhammad-Nizam-Uddin](https://reader036.vdocument.in/reader036/viewer/2022062320/55c4f7a9bb61eb38508b46b4/html5/thumbnails/41.jpg)
Non pharmacologic management
Achieve additional benefits with supplementary intake of foods containing lipid-lowering nutrients such as n-3 fatty acids, dietary fibre and plant sterols.
![Page 42: Dyslipidemiaandmanagementofdyslipidemia-by Muhammad-Nizam-Uddin](https://reader036.vdocument.in/reader036/viewer/2022062320/55c4f7a9bb61eb38508b46b4/html5/thumbnails/42.jpg)
Pharmacologic Management
![Page 43: Dyslipidemiaandmanagementofdyslipidemia-by Muhammad-Nizam-Uddin](https://reader036.vdocument.in/reader036/viewer/2022062320/55c4f7a9bb61eb38508b46b4/html5/thumbnails/43.jpg)
![Page 44: Dyslipidemiaandmanagementofdyslipidemia-by Muhammad-Nizam-Uddin](https://reader036.vdocument.in/reader036/viewer/2022062320/55c4f7a9bb61eb38508b46b4/html5/thumbnails/44.jpg)
Nutrient Recommendations of TLC Diet
Nutrient Recommended Intake
Saturated fat < 7% of total calories Polyunsaturated fat Up to 10% of total calories Monounsaturated fat Up to 20% of total calories Total fat 25-30% of total calories Carbohydrates 50-60% of total calories Fiber 20-30 grams/day Protein Approx. 15% of total calories Cholesterol <200 mg/day Total calories Balance energy intake and
expenditure to maintain desirable body
weight/prevent weight gain
![Page 45: Dyslipidemiaandmanagementofdyslipidemia-by Muhammad-Nizam-Uddin](https://reader036.vdocument.in/reader036/viewer/2022062320/55c4f7a9bb61eb38508b46b4/html5/thumbnails/45.jpg)
Lipid Lowering DrugsHMG-CoA Reductase Inhibitors (Statins)
Partially block an enzyme necessary for formation of cholesterol
Speed removal of LDL from blood 18%-60% reduction in LDL Most effective at lowering LDL; esp. HS dosing Liver enzymes MUST be monitored. Check
baseline, 3mos., then semi-annually (D/C if > 3x normal limits)
Side effects: Myalgias (D/C if total CK >10x normal), rhabdomyolysis
Metabolized by CP450 (watch for drug interactions)
Contraindicated in pregnancy.
![Page 46: Dyslipidemiaandmanagementofdyslipidemia-by Muhammad-Nizam-Uddin](https://reader036.vdocument.in/reader036/viewer/2022062320/55c4f7a9bb61eb38508b46b4/html5/thumbnails/46.jpg)
Different statins
AtorvastatinSimvastatinRosuvastatinPitavastatinFluvastatin
Pravastatin
![Page 47: Dyslipidemiaandmanagementofdyslipidemia-by Muhammad-Nizam-Uddin](https://reader036.vdocument.in/reader036/viewer/2022062320/55c4f7a9bb61eb38508b46b4/html5/thumbnails/47.jpg)
Lipid Lowering Drugs
Bile Acid Sequestrants:Cholestyramin , Cholestipol
Convert cholesterol to bile acids Bind bile acids and prevent
reabsorption in the gut May increase triglyceride levels Most common side effects: GI-
constipation Alternative for statins
![Page 48: Dyslipidemiaandmanagementofdyslipidemia-by Muhammad-Nizam-Uddin](https://reader036.vdocument.in/reader036/viewer/2022062320/55c4f7a9bb61eb38508b46b4/html5/thumbnails/48.jpg)
Lipid Lowering DrugsCholesterol Absorption Inhibitor(Ezetimibea):
Monotherapy or in combination with statin Not recommended with fibrates Reduces LDL number : esp. Lp(a)
hepatic LDL receptor,Inhibit intestinal mucosa transporter NPCILT.
Lipid-Regulating Agent: Omega 3 acid ethyl esters
Omega 3 Fish oil (salmon, herring, mackerel, swordfish, albacore tuna, sardines, lake trout)
Only FDA approved supplement for tx of dyslipidemias
Decreases hepatic production of TG and VLDL Increases LDL size to large buoyant particles
![Page 49: Dyslipidemiaandmanagementofdyslipidemia-by Muhammad-Nizam-Uddin](https://reader036.vdocument.in/reader036/viewer/2022062320/55c4f7a9bb61eb38508b46b4/html5/thumbnails/49.jpg)
Lipid Lowering DrugsNicotinic Acid/Niacin (B3)
Inhibition of lipolysis
Reduces production and release of LDL Effective in reduction of triglycerides
(<400mg/dl) Increases HDL Very effective in increasing LDL particle
size Monitor liver enzymes and glucose Most common side effect: FLUSHING (take
ASA/ibuprofen 30 min. prior and take with light snack). Decreased with time released formulas
Liver function disterbance Exacerbation of gout and hyperglycemia.
![Page 50: Dyslipidemiaandmanagementofdyslipidemia-by Muhammad-Nizam-Uddin](https://reader036.vdocument.in/reader036/viewer/2022062320/55c4f7a9bb61eb38508b46b4/html5/thumbnails/50.jpg)
Lipid Lowering Drugs
Fibric Acid Derivatives/Fibrates
M/A: PPAR∞- stimulation metabolism of TG & LDL Very effective in reducing triglycerides
(>400) Increase HDL SIE: Myolgia,Myopathy,Abnormal LFT,Choleclithiasis Containdications: Gallbladder disease,
hepatic disease, renal dysfunction Increase LDL particle size but not
quantity Caution with statins Gemfibrozil, Benza fibrates, feno fibrates.
![Page 51: Dyslipidemiaandmanagementofdyslipidemia-by Muhammad-Nizam-Uddin](https://reader036.vdocument.in/reader036/viewer/2022062320/55c4f7a9bb61eb38508b46b4/html5/thumbnails/51.jpg)
![Page 52: Dyslipidemiaandmanagementofdyslipidemia-by Muhammad-Nizam-Uddin](https://reader036.vdocument.in/reader036/viewer/2022062320/55c4f7a9bb61eb38508b46b4/html5/thumbnails/52.jpg)
Monitoring of therapy After 6 weeks ( 12 weeks for fibrates) Parameter:1. Lipid response2. Side effects- CK, LFT3. Others-a) Dietary compliance
b) Exercise c) Cardiovascular signs and
symptomsd) Wt. e) BP
![Page 53: Dyslipidemiaandmanagementofdyslipidemia-by Muhammad-Nizam-Uddin](https://reader036.vdocument.in/reader036/viewer/2022062320/55c4f7a9bb61eb38508b46b4/html5/thumbnails/53.jpg)
Summary Dyslipidemia(Silent killer)
Artherosclerosis MI,Stroke At least 12 hrs fasting for the
measurement of lipid profile. TLC-very important But usually
ignored Statin-(Commission is better than
omission)widely well tolerated Other risk factors should be
addressed appropriately.
![Page 54: Dyslipidemiaandmanagementofdyslipidemia-by Muhammad-Nizam-Uddin](https://reader036.vdocument.in/reader036/viewer/2022062320/55c4f7a9bb61eb38508b46b4/html5/thumbnails/54.jpg)
Act Commission is Better than
Omission
![Page 55: Dyslipidemiaandmanagementofdyslipidemia-by Muhammad-Nizam-Uddin](https://reader036.vdocument.in/reader036/viewer/2022062320/55c4f7a9bb61eb38508b46b4/html5/thumbnails/55.jpg)
THANK YOU